Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3) Oestrogen Receptor Negative Breast Cancer.

Trial Profile

Randomised Placebo-controlled Phase II Trial of Preoperative Therapy With Gefitinib (Iressa/ZD1839) and Epirubicin-Cyclophosphamide in Patients With Primary Operable (T2-T3) Oestrogen Receptor Negative Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2011

At a glance

  • Drugs Cyclophosphamide; Epirubicin; Gefitinib
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms NICE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Jul 2011 Results of an analysis investigating estrogen receptor expression published in Breast Cancer Research and Treatment.
    • 16 Dec 2007 Status changed from recruiting to completed.
    • 01 May 2007 Primary endpoint 'Complete-pathological-response-rate' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top